|
New York, NY - February 10, 2003 - The National Advertising
Division (NAD) of the Council of Better Business Bureaus,
Inc., the advertising industry's self-regulatory forum, announced
that Global Vision, Inc. had sufficient evidence to support
its basic claim that its products Avacor was safe and effective
in the treatment of androgenic alopecia.
However,
NAD recommended that Global Vision modify its advertising
and labeling claims to avoid consumer confusion and a potential
health hazard. The truth and accuracy of Global Vision's advertising
was initiated by NAD through its routine and on-going monitoring
program and subsequently challenged by The Bald Truth Foundation,
a consumer advocacy group focused on hair loss prevention
products.
NAD acknowledged that the advertiser's prior discontinuance
of the product’s labeling and its replacement of labeling
in conformance with FDA guidelines including the proper disclosure
and labeling of the drug Minoxidil as an active ingredient
in the topical formulation with full disclosure of all relevant
warnings concomitant to the use of Minoxidil, the discontinuance
of “all natural” claims to the product as a whole,
and the discontinuance of 90%+ success rate claim for the
product, were necessary and appropriate to avoid consumer
confusion and a potential health hazard.
In a statement to NAD, the advertiser stated that it supports
and appreciates NAD's self-regulatory process and it's careful
and thorough review of the case. The advertiser further stated
that, "… it was pleased to accept the modifications
recommended by the NAD" and "… is gratified
that the NAD has found that its Avacor system is safe and
effective in the treatment of androgenic alopecia …"
|
